Semax

Research Papers on Semax

Based on the available research literature, Semax appears to be a synthetic peptide derived from ACTH (adrenocorticotropic hormone) that has been studied primarily in animal models for neurological conditions.

The most directly relevant study examined Semax's potential for treating Alzheimer's disease in an animal model (PMID: 41479572, published in Acta naturae, 2025). However, the specific study design, sample size, and detailed findings are not provided in the available evidence.

Another study investigated how Semax affects calcium dynamics in rat brain neurons (PMID: 41171324, Bulletin of Experimental Biology and Medicine, 2025), suggesting research interest in the compound's neurological mechanisms of action.

There is also research on a related ACTH-derived peptide (ACTH4-10Pro8-Gly9-Pro10) that examined anti-inflammatory effects in a spinal cord injury model using male Sprague Dawley rats (PMID: 41179234, F1000Research, 2023), though this appears to be a different but structurally related compound.

Important limitations: The evidence for Semax is quite limited. No human clinical trials were identified in the search results. The available studies appear to be primarily preclinical research conducted in animal models. The abstracts and detailed methodologies for these studies are not provided, making it impossible to assess study quality, sample sizes, or the strength of the evidence.

Disclaimer: This information is for educational purposes only and should not be considered medical advice. Consult with a healthcare provider before considering any experimental treatments.